Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia
Atypical chronic myeloid leukemia (aCML) occurs rarely and is associated with a poor prognosis when treated with conventional chemotherapy. We evaluated the outcome of aCML after allogeneic hematopoietic stem cell transplantation (HSCT). Nine patients were transplanted from HLA-identical siblings (n...
Gespeichert in:
| Veröffentlicht in: | Bone marrow transplantation (Basingstoke) 2004-12, Vol.34 (12), p.1047-1050 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1050 |
|---|---|
| container_issue | 12 |
| container_start_page | 1047 |
| container_title | Bone marrow transplantation (Basingstoke) |
| container_volume | 34 |
| creator | KOLDEHOFF, M BEELEN, D. W TRENSCHEL, R STECKEL, N. K PECENY, R DITSCHKOWSKI, M OTTINGER, H ELMAAGACLI, A. H |
| description | Atypical chronic myeloid leukemia (aCML) occurs rarely and is associated with a poor prognosis when treated with conventional chemotherapy. We evaluated the outcome of aCML after allogeneic hematopoietic stem cell transplantation (HSCT). Nine patients were transplanted from HLA-identical siblings (n = 4), HLA-compatible unrelated donors (n = 4) or twin brother (n = 1). Median follow-up was 55 months after transplant (range, 9.1-118.1 months). One patient who was transplanted in advanced disease with bone marrow from his twin brother relapsed 19 months post transplant. This patient was successfully retransplanted from the original donor. All patients remained in complete remission. Analysis of the leukocyte chimerism of peripheral white blood cells and bone marrow buffy coat cells by VNTR-polymerase chain reaction (PCR) and single-nucleotide polymorphism real-time PCR revealed complete chimerism in all patients who had received an allogeneic transplant. One patient suffering from cerebral toxoplasmosis died 9 months post transplant. All other patients were alive at the time of analysis. Our findings suggest that the outcome of allogeneic or syngeneic transplantation in patients with aCML may not be worse than the outcome of transplantation for BCR-ABL-positive CML. |
| doi_str_mv | 10.1038/sj.bmt.1704686 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_67132525</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A182366394</galeid><sourcerecordid>A182366394</sourcerecordid><originalsourceid>FETCH-LOGICAL-c569t-e1dc5614399e1c22bed179f9e59a571a22e0ca416da8b7c315d1f57370fd2d7d3</originalsourceid><addsrcrecordid>eNqFkt2L1DAUxYso7rj66psSFPetY28-28dl8QsW9kWfQya9tRnbpDYpy_z3ZpjCqKxIHhLC79zLufcUxUuotlCx-n3cb3dj2oKquKzlo2IDXMlSMCkeF5uKyrpkTDYXxbMY91UFnFfiaXEBQoBsuNwUeLckG0YkoSM9jiaFKThMzpKYcCQWh4Gk2fg4DcYnk1zwxHky5Rf6FMm9Sz0x6TA5awZi-zn4rB0POATXkgGXHzg687x40pkh4ov1viy-ffzw9eZzeXv36cvN9W1phWxSidDmB3DWNAiW0h22oJquQdEYocBQipU1HGRr6p2yDEQLnVBMVV1LW9Wyy-LqVHeaw88FY9Kji0cPxmNYopYKGBVU_BcEVQtRK5bBt3-B-7DMPpvQVHIKXApOM_XmnxRImQ2p5lzquxlQO9-FPFh77KuvoaZMStbwTG0foPJp8yBt8Ni5_P-H4Oo3QY9mSH0Mw3JcVXywsp1DjDN2eprdaOaDhkofw6TjXucw6TVMWfB6dbXsRmzP-JqeDLxbARPz-rucE-vimZN5Q6dpvzpx3qRlxjOwNvoFaEbabg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>216643979</pqid></control><display><type>article</type><title>Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia</title><source>MEDLINE</source><source>Nature Journals Online</source><source>EZB-FREE-00999 freely available EZB journals</source><source>SpringerLink Journals - AutoHoldings</source><creator>KOLDEHOFF, M ; BEELEN, D. W ; TRENSCHEL, R ; STECKEL, N. K ; PECENY, R ; DITSCHKOWSKI, M ; OTTINGER, H ; ELMAAGACLI, A. H</creator><creatorcontrib>KOLDEHOFF, M ; BEELEN, D. W ; TRENSCHEL, R ; STECKEL, N. K ; PECENY, R ; DITSCHKOWSKI, M ; OTTINGER, H ; ELMAAGACLI, A. H</creatorcontrib><description>Atypical chronic myeloid leukemia (aCML) occurs rarely and is associated with a poor prognosis when treated with conventional chemotherapy. We evaluated the outcome of aCML after allogeneic hematopoietic stem cell transplantation (HSCT). Nine patients were transplanted from HLA-identical siblings (n = 4), HLA-compatible unrelated donors (n = 4) or twin brother (n = 1). Median follow-up was 55 months after transplant (range, 9.1-118.1 months). One patient who was transplanted in advanced disease with bone marrow from his twin brother relapsed 19 months post transplant. This patient was successfully retransplanted from the original donor. All patients remained in complete remission. Analysis of the leukocyte chimerism of peripheral white blood cells and bone marrow buffy coat cells by VNTR-polymerase chain reaction (PCR) and single-nucleotide polymorphism real-time PCR revealed complete chimerism in all patients who had received an allogeneic transplant. One patient suffering from cerebral toxoplasmosis died 9 months post transplant. All other patients were alive at the time of analysis. Our findings suggest that the outcome of allogeneic or syngeneic transplantation in patients with aCML may not be worse than the outcome of transplantation for BCR-ABL-positive CML.</description><identifier>ISSN: 0268-3369</identifier><identifier>EISSN: 1476-5365</identifier><identifier>DOI: 10.1038/sj.bmt.1704686</identifier><identifier>PMID: 15516946</identifier><identifier>CODEN: BMTRE9</identifier><language>eng</language><publisher>Basingstoke: Nature Publishing Group</publisher><subject>Adult ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; BCR-ABL protein ; Biological and medical sciences ; Bone marrow ; Bone marrow transplantation ; Bone marrow, stem cells transplantation. Graft versus host reaction ; Buffy coat ; Care and treatment ; Chemotherapy ; Chimerism ; Chronic myeloid leukemia ; Diagnosis ; Female ; Follow-Up Studies ; Fusion protein ; Genetic aspects ; Graft vs Host Disease ; Health aspects ; Hematologic and hematopoietic diseases ; Hematopoietic Stem Cell Transplantation - adverse effects ; Hematopoietic Stem Cell Transplantation - methods ; Hematopoietic stem cells ; Histocompatibility antigen HLA ; Humans ; Leukemia ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - classification ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Leukocytes ; Male ; Medical sciences ; Middle Aged ; Myeloid leukemia ; Nucleotides ; Opportunistic Infections ; Patient outcomes ; Patients ; Polymerase chain reaction ; Polymorphism ; Remission ; Remission Induction ; Retrospective Studies ; Single-nucleotide polymorphism ; Stem cell transplantation ; Stem cells ; Syngeneic grafts ; Tissue Donors ; Toxoplasmosis ; Transfusions. Complications. Transfusion reactions. Cell and gene therapy ; Transplantation ; Transplantation Chimera ; Transplantation, Homologous ; Transplantation, Isogeneic ; Treatment Outcome ; Twins</subject><ispartof>Bone marrow transplantation (Basingstoke), 2004-12, Vol.34 (12), p.1047-1050</ispartof><rights>2005 INIST-CNRS</rights><rights>Bone Marrow Transplantation (2004).</rights><rights>COPYRIGHT 2004 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Dec 2004</rights><rights>Nature Publishing Group 2004.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c569t-e1dc5614399e1c22bed179f9e59a571a22e0ca416da8b7c315d1f57370fd2d7d3</citedby><cites>FETCH-LOGICAL-c569t-e1dc5614399e1c22bed179f9e59a571a22e0ca416da8b7c315d1f57370fd2d7d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2726,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16315525$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15516946$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KOLDEHOFF, M</creatorcontrib><creatorcontrib>BEELEN, D. W</creatorcontrib><creatorcontrib>TRENSCHEL, R</creatorcontrib><creatorcontrib>STECKEL, N. K</creatorcontrib><creatorcontrib>PECENY, R</creatorcontrib><creatorcontrib>DITSCHKOWSKI, M</creatorcontrib><creatorcontrib>OTTINGER, H</creatorcontrib><creatorcontrib>ELMAAGACLI, A. H</creatorcontrib><title>Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia</title><title>Bone marrow transplantation (Basingstoke)</title><addtitle>Bone Marrow Transplant</addtitle><description>Atypical chronic myeloid leukemia (aCML) occurs rarely and is associated with a poor prognosis when treated with conventional chemotherapy. We evaluated the outcome of aCML after allogeneic hematopoietic stem cell transplantation (HSCT). Nine patients were transplanted from HLA-identical siblings (n = 4), HLA-compatible unrelated donors (n = 4) or twin brother (n = 1). Median follow-up was 55 months after transplant (range, 9.1-118.1 months). One patient who was transplanted in advanced disease with bone marrow from his twin brother relapsed 19 months post transplant. This patient was successfully retransplanted from the original donor. All patients remained in complete remission. Analysis of the leukocyte chimerism of peripheral white blood cells and bone marrow buffy coat cells by VNTR-polymerase chain reaction (PCR) and single-nucleotide polymorphism real-time PCR revealed complete chimerism in all patients who had received an allogeneic transplant. One patient suffering from cerebral toxoplasmosis died 9 months post transplant. All other patients were alive at the time of analysis. Our findings suggest that the outcome of allogeneic or syngeneic transplantation in patients with aCML may not be worse than the outcome of transplantation for BCR-ABL-positive CML.</description><subject>Adult</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>BCR-ABL protein</subject><subject>Biological and medical sciences</subject><subject>Bone marrow</subject><subject>Bone marrow transplantation</subject><subject>Bone marrow, stem cells transplantation. Graft versus host reaction</subject><subject>Buffy coat</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Chimerism</subject><subject>Chronic myeloid leukemia</subject><subject>Diagnosis</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Fusion protein</subject><subject>Genetic aspects</subject><subject>Graft vs Host Disease</subject><subject>Health aspects</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Hematopoietic stem cells</subject><subject>Histocompatibility antigen HLA</subject><subject>Humans</subject><subject>Leukemia</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - classification</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Leukocytes</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myeloid leukemia</subject><subject>Nucleotides</subject><subject>Opportunistic Infections</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Polymerase chain reaction</subject><subject>Polymorphism</subject><subject>Remission</subject><subject>Remission Induction</subject><subject>Retrospective Studies</subject><subject>Single-nucleotide polymorphism</subject><subject>Stem cell transplantation</subject><subject>Stem cells</subject><subject>Syngeneic grafts</subject><subject>Tissue Donors</subject><subject>Toxoplasmosis</subject><subject>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</subject><subject>Transplantation</subject><subject>Transplantation Chimera</subject><subject>Transplantation, Homologous</subject><subject>Transplantation, Isogeneic</subject><subject>Treatment Outcome</subject><subject>Twins</subject><issn>0268-3369</issn><issn>1476-5365</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkt2L1DAUxYso7rj66psSFPetY28-28dl8QsW9kWfQya9tRnbpDYpy_z3ZpjCqKxIHhLC79zLufcUxUuotlCx-n3cb3dj2oKquKzlo2IDXMlSMCkeF5uKyrpkTDYXxbMY91UFnFfiaXEBQoBsuNwUeLckG0YkoSM9jiaFKThMzpKYcCQWh4Gk2fg4DcYnk1zwxHky5Rf6FMm9Sz0x6TA5awZi-zn4rB0POATXkgGXHzg687x40pkh4ov1viy-ffzw9eZzeXv36cvN9W1phWxSidDmB3DWNAiW0h22oJquQdEYocBQipU1HGRr6p2yDEQLnVBMVV1LW9Wyy-LqVHeaw88FY9Kji0cPxmNYopYKGBVU_BcEVQtRK5bBt3-B-7DMPpvQVHIKXApOM_XmnxRImQ2p5lzquxlQO9-FPFh77KuvoaZMStbwTG0foPJp8yBt8Ni5_P-H4Oo3QY9mSH0Mw3JcVXywsp1DjDN2eprdaOaDhkofw6TjXucw6TVMWfB6dbXsRmzP-JqeDLxbARPz-rucE-vimZN5Q6dpvzpx3qRlxjOwNvoFaEbabg</recordid><startdate>20041201</startdate><enddate>20041201</enddate><creator>KOLDEHOFF, M</creator><creator>BEELEN, D. W</creator><creator>TRENSCHEL, R</creator><creator>STECKEL, N. K</creator><creator>PECENY, R</creator><creator>DITSCHKOWSKI, M</creator><creator>OTTINGER, H</creator><creator>ELMAAGACLI, A. H</creator><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20041201</creationdate><title>Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia</title><author>KOLDEHOFF, M ; BEELEN, D. W ; TRENSCHEL, R ; STECKEL, N. K ; PECENY, R ; DITSCHKOWSKI, M ; OTTINGER, H ; ELMAAGACLI, A. H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c569t-e1dc5614399e1c22bed179f9e59a571a22e0ca416da8b7c315d1f57370fd2d7d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>BCR-ABL protein</topic><topic>Biological and medical sciences</topic><topic>Bone marrow</topic><topic>Bone marrow transplantation</topic><topic>Bone marrow, stem cells transplantation. Graft versus host reaction</topic><topic>Buffy coat</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Chimerism</topic><topic>Chronic myeloid leukemia</topic><topic>Diagnosis</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Fusion protein</topic><topic>Genetic aspects</topic><topic>Graft vs Host Disease</topic><topic>Health aspects</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Hematopoietic stem cells</topic><topic>Histocompatibility antigen HLA</topic><topic>Humans</topic><topic>Leukemia</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - classification</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Leukocytes</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myeloid leukemia</topic><topic>Nucleotides</topic><topic>Opportunistic Infections</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Polymerase chain reaction</topic><topic>Polymorphism</topic><topic>Remission</topic><topic>Remission Induction</topic><topic>Retrospective Studies</topic><topic>Single-nucleotide polymorphism</topic><topic>Stem cell transplantation</topic><topic>Stem cells</topic><topic>Syngeneic grafts</topic><topic>Tissue Donors</topic><topic>Toxoplasmosis</topic><topic>Transfusions. Complications. Transfusion reactions. Cell and gene therapy</topic><topic>Transplantation</topic><topic>Transplantation Chimera</topic><topic>Transplantation, Homologous</topic><topic>Transplantation, Isogeneic</topic><topic>Treatment Outcome</topic><topic>Twins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KOLDEHOFF, M</creatorcontrib><creatorcontrib>BEELEN, D. W</creatorcontrib><creatorcontrib>TRENSCHEL, R</creatorcontrib><creatorcontrib>STECKEL, N. K</creatorcontrib><creatorcontrib>PECENY, R</creatorcontrib><creatorcontrib>DITSCHKOWSKI, M</creatorcontrib><creatorcontrib>OTTINGER, H</creatorcontrib><creatorcontrib>ELMAAGACLI, A. H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Bone marrow transplantation (Basingstoke)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KOLDEHOFF, M</au><au>BEELEN, D. W</au><au>TRENSCHEL, R</au><au>STECKEL, N. K</au><au>PECENY, R</au><au>DITSCHKOWSKI, M</au><au>OTTINGER, H</au><au>ELMAAGACLI, A. H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia</atitle><jtitle>Bone marrow transplantation (Basingstoke)</jtitle><addtitle>Bone Marrow Transplant</addtitle><date>2004-12-01</date><risdate>2004</risdate><volume>34</volume><issue>12</issue><spage>1047</spage><epage>1050</epage><pages>1047-1050</pages><issn>0268-3369</issn><eissn>1476-5365</eissn><coden>BMTRE9</coden><abstract>Atypical chronic myeloid leukemia (aCML) occurs rarely and is associated with a poor prognosis when treated with conventional chemotherapy. We evaluated the outcome of aCML after allogeneic hematopoietic stem cell transplantation (HSCT). Nine patients were transplanted from HLA-identical siblings (n = 4), HLA-compatible unrelated donors (n = 4) or twin brother (n = 1). Median follow-up was 55 months after transplant (range, 9.1-118.1 months). One patient who was transplanted in advanced disease with bone marrow from his twin brother relapsed 19 months post transplant. This patient was successfully retransplanted from the original donor. All patients remained in complete remission. Analysis of the leukocyte chimerism of peripheral white blood cells and bone marrow buffy coat cells by VNTR-polymerase chain reaction (PCR) and single-nucleotide polymorphism real-time PCR revealed complete chimerism in all patients who had received an allogeneic transplant. One patient suffering from cerebral toxoplasmosis died 9 months post transplant. All other patients were alive at the time of analysis. Our findings suggest that the outcome of allogeneic or syngeneic transplantation in patients with aCML may not be worse than the outcome of transplantation for BCR-ABL-positive CML.</abstract><cop>Basingstoke</cop><pub>Nature Publishing Group</pub><pmid>15516946</pmid><doi>10.1038/sj.bmt.1704686</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0268-3369 |
| ispartof | Bone marrow transplantation (Basingstoke), 2004-12, Vol.34 (12), p.1047-1050 |
| issn | 0268-3369 1476-5365 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67132525 |
| source | MEDLINE; Nature Journals Online; EZB-FREE-00999 freely available EZB journals; SpringerLink Journals - AutoHoldings |
| subjects | Adult Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy BCR-ABL protein Biological and medical sciences Bone marrow Bone marrow transplantation Bone marrow, stem cells transplantation. Graft versus host reaction Buffy coat Care and treatment Chemotherapy Chimerism Chronic myeloid leukemia Diagnosis Female Follow-Up Studies Fusion protein Genetic aspects Graft vs Host Disease Health aspects Hematologic and hematopoietic diseases Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic Stem Cell Transplantation - methods Hematopoietic stem cells Histocompatibility antigen HLA Humans Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - classification Leukemia, Myelogenous, Chronic, BCR-ABL Positive - complications Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Leukocytes Male Medical sciences Middle Aged Myeloid leukemia Nucleotides Opportunistic Infections Patient outcomes Patients Polymerase chain reaction Polymorphism Remission Remission Induction Retrospective Studies Single-nucleotide polymorphism Stem cell transplantation Stem cells Syngeneic grafts Tissue Donors Toxoplasmosis Transfusions. Complications. Transfusion reactions. Cell and gene therapy Transplantation Transplantation Chimera Transplantation, Homologous Transplantation, Isogeneic Treatment Outcome Twins |
| title | Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T15%3A29%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcome%20of%20hematopoietic%20stem%20cell%20transplantation%20in%20patients%20with%20atypical%20chronic%20myeloid%20leukemia&rft.jtitle=Bone%20marrow%20transplantation%20(Basingstoke)&rft.au=KOLDEHOFF,%20M&rft.date=2004-12-01&rft.volume=34&rft.issue=12&rft.spage=1047&rft.epage=1050&rft.pages=1047-1050&rft.issn=0268-3369&rft.eissn=1476-5365&rft.coden=BMTRE9&rft_id=info:doi/10.1038/sj.bmt.1704686&rft_dat=%3Cgale_proqu%3EA182366394%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=216643979&rft_id=info:pmid/15516946&rft_galeid=A182366394&rfr_iscdi=true |